Selected article for: "blood brain barrier and case report"

Author: Gerstein, Shawn; Gautam-Goyal, Pranisha; Goyal, Sameer
Title: A case of Listeria monocytogenes meningitis complicated by Hydrocephalus and Intraventricular hemorrhage: A review of treatment options and outcomes
  • Document date: 2020_1_18
  • ID: j7mcry3l_9
    Snippet: The use of intrathecal/intraventricular antimicrobials in this setting has not been well studied. A review of the existing literature reveals no standard protocol for the administration of intraventricular antimicrobials in the setting of CNS infections [10] . The risk reward profile focuses on the advantages of higher doses of antimicrobials in the CSF than can cross the blood brain barrier alone versus the increased risk of toxicity. A clinical.....
    Document: The use of intrathecal/intraventricular antimicrobials in this setting has not been well studied. A review of the existing literature reveals no standard protocol for the administration of intraventricular antimicrobials in the setting of CNS infections [10] . The risk reward profile focuses on the advantages of higher doses of antimicrobials in the CSF than can cross the blood brain barrier alone versus the increased risk of toxicity. A clinical cohort study by Shoft and colleagues found a mortality benefit with no significant adverse events when utilizing intraventricular antimicrobials alongside systemic antimicrobials in a population of postneurosurgical patients [11] . A case report by Richards and colleagues demonstrated the efficacy of using intraventricular antimicrobials in a patient with recurrent Listeria monocytogenes meningitis following treatment failure with systemic therapy alone [12] .

    Search related documents:
    Co phrase search for related documents
    • adverse event and blood brain barrier: 1
    • adverse event and blood brain barrier cross: 1
    • adverse event and case report: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • adverse event and clinical cohort: 1, 2, 3, 4, 5, 6
    • adverse event and clinical cohort study: 1, 2, 3
    • adverse event and high dose: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • adverse event and increase risk: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10
    • blood brain and case report: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13
    • blood brain and clinical cohort: 1
    • blood brain and CNS infection: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24
    • blood brain and high dose: 1, 2
    • blood brain and increase risk: 1, 2, 3
    • blood brain barrier and case report: 1, 2, 3, 4, 5
    • blood brain barrier and CNS infection: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18
    • blood brain barrier and high dose: 1, 2
    • blood brain barrier and increase risk: 1, 2
    • blood brain barrier cross and case report: 1, 2
    • blood brain barrier cross and CNS infection: 1, 2
    • blood brain barrier cross and increase risk: 1